In Vivo Evolution of CTX-M-215, a Novel Narrow-Spectrum β-Lactamase in an Escherichia coli Clinical Isolate Conferring Resistance to Mecillinam

Antimicrob Agents Chemother. 2020 Oct 20;64(11):e00562-20. doi: 10.1128/AAC.00562-20. Print 2020 Oct 20.

Abstract

Here, we report a novel narrow-spectrum β-lactamase CTX-M-215 identified in an Escherichia coli clinical isolate in China and conferring high-level resistance to mecillinam but not to cefotaxime. CTX-M-215 differed from CTX-M-125, a CTX-M extended-spectrum β-lactamase (ESBL), by an N132D substitution, which decreased hydrolytic activities toward penicillins and cephalosporins except for mecillinam. High similarity was observed between CTX-M-215- and CTX-M-125-bearing plasmids, carried by different isolates in the same patient, indicating in vivo evolution of CTX-M-215 from CTX-M-125.

Keywords: CTX-M-type enzyme; N132D; cefotaxime; mecillinam; narrow-spectrum β-lactamase.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amdinocillin
  • Anti-Bacterial Agents / pharmacology
  • China
  • Escherichia coli / genetics
  • Escherichia coli Infections* / drug therapy
  • Humans
  • Microbial Sensitivity Tests
  • Plasmids / genetics
  • beta-Lactamases* / genetics

Substances

  • Anti-Bacterial Agents
  • beta-Lactamases
  • Amdinocillin